skip navigation
  Text size: S  M  L
Health Funding News Laboratories Education Jobs About NEI Resources Help Viewing Site
Home » News and Events » NIH-Sponsored Study Stopped: New Drug Does Not Control AIDS-Related Eye Disease, August 15, 1996
News and Events

CONTACT: Judith Stein
(301) 496-5248

NEI Press Release
National Eye Institute

August 15, 1996

NIH-Sponsored Study Stopped:
New Drug Does Not Control AIDS-Related Eye Disease

Researchers have stopped patient enrollment and treatment in a study designed to evaluate the safety and effectiveness of a new drug to treat a blinding eye infection common in people with AIDS. The drug, MSL 109 (ProtovirTM), did not slow the progression of CMV retinitis, the eye infection, in a clinical trial sponsored by the National Eye Institute (NEI) of the National Institutes of Health.

At the time the study was stopped, 209 of the 325 patients planned for the study had been treated. Of those, approximately 40% were newly diagnosed with CMV retinitis and 60% had previously been diagnosed with, and treated for, the disease. The patients were randomized to receive either MSL 109 or a placebo.

The investigators decided to terminate enrollment and treatment following the recommendation of an independent data and safety monitoring board. The recommendation was based on the lack of evidence of efficacy of MSL 109 for the treatment of CMV retinitis. The median time to progression of disease was 65 days in the group treated with MSL 109 and 66 days in the group taking the placebo.

In addition, study results suggest that patients with recurrent CMV retinitis who were taking the new drug had a higher mortality rate than similar patients taking a placebo. However, the meaning of this mortality difference was unclear because among this same group of study patients there was a lower than expected mortality rate in those given the placebo. The mortality difference was not observed in patients with newly-diagnosed CMV retinitis.

"These results highlight the importance of conducting clinical trials to evaluate new therapies," said Carl Kupfer, M.D., National Eye Institute director.

Up to 40 percent of people with AIDS develop CMV retinitis, which is caused by an organism called cytomegalovirus (CMV). Untreated, the disease destroys the retina, the light-sensing tissue that lines the back of the eye and is crucial for vision.

People with AIDS are among those most vulnerable to CMV, because their weakened immune systems are unable to resist potentially harmful organisms. Most people have been exposed to CMV, but their healthy immune systems do not allow infections to develop.

The Monoclonal Antibody CMV Retinitis Trial (MACRT), a nationwide, randomized, placebo-controlled study, tested MSL 109, a drug that mimics the body's natural reaction to a foreign organism by acting like antibodies that are produced normally in healthy humans. MSL 109 mimics the body's antibody to the CMV virus. Patients in the study received either MSL 109 or a placebo as supplementary therapy to their primary treatment for CMV retinitis. The purpose of the study was to see if the supplementary therapy would keep the disease from spreading for a longer time period than their primary treatment alone.

A list of centers that participated in the study is attached.

The National Eye Institute is the Federal government's lead agency for vision research, and supports more than 80 percent of such research conducted in the United States. The MACRT study is part of a collaborative research group, Studies of the Ocular Complications of AIDS (SOCA), which was established through the National Institutes of Health. The SOCA study of MSL 109 was performed with funding from the National Eye Institute and Protein Design Labs, Inc., in collaboration with the National Institute of Allergy and Infectious Diseases' AIDS Clinical Trials Group.

# # #

Participating Clinical Centers
Monoclonal Antibody CMV-Retinitis Trial

Gary N. Holland, M.D.
Jules Stein Eye Institute
University of California,
Los Angeles
(310) 825-9508

William R. Freeman, M.D.
Shiley Eye Center
University of California,
San Diego
(619) 534-3513

James O'Donnell, M.D.
Beckman Vision Center
University of California,
San Francisco
(415) 476-1921

Janet Davis, M.D.
Bascom Palmer Eye Institute
University of Miami
(305) 326-6377

Peter R. Pavan, M.D.
University of South Florida
(813) 974-1530

Daniel F. Martin, M.D.
The Emory Eye Clinic
Emory University
(404) 778-4815

David V. Weinberg, M.D.
Department of Ophthalmology
Northwestern University
(312) 908-8152

Bruce A. Barron, M.D.
LSU Eye Center
Louisiana State University
Medical Center
New Orleans
(504) 568-6700 ext. 307

James P. Dunn, M.D.
The Wilmer Ophthalmological Institute
The Johns Hopkins University
School of Medicine
(410) 955-2966

New Jersey
Ronald Rescigno, M.D.
UMDNJ-New Jersey
Medical School
(201) 982-2065

New York
Murk-Hein Heinemann, M.D.
New York Hospital-Cornell Medical Center
(212) 746-2483

Alan H. Friedman, M.D.
Mount Sinai School of Medicine
New York City
(212) 241-6241

Dorothy Friedberg, M.D.
New York University
Medical Center
New York
(212) 687-0265

North Carolina
Charles van der Horst, M.D.
University of North Carolina
at Chapel Hill
(919) 966-2536

Richard Alan Lewis, M.D.
Cullen Eye Institute
Baylor College of Medicine
(713) 798-6100
Resource Centers:

Chairman's Office
Douglas A. Jabs, M.D.
The Wilmer Ophthalmological Institute
The Johns Hopkins University School of Medicine
Baltimore, Maryland
(410) 955-1966

Coordinating Center
Curtis L. Meinert, Ph.D.
School of Hygiene and Public Health
The Johns Hopkins University
Baltimore, Baltimore
(410) 955-8198

Fundus Photograph Reading Center
Matthew D. Davis, M.D.
Department of Ophthalmology
University of Wisconsin
Madison, Wisconsin
(608) 263-6071

Drug Distribution Center:
Mark Walls, R.Ph.
McKessan BioServices
Rockville, Maryland
(301) 762-0069

Central Laboratories/Repository:
Richard B. Pollard, M.D.
University of Texas Medical Branch
Galveston, Texas
(409) 772-4979

Colin Jordan, M.D.
Division of Infectious Diseases
University of Minnesota
Minneapolis, Minnesota
(612) 624-9996

NEI Representative:
Natalie Kurinij, Ph.D.
National Eye Institute
(301) 496-5983

June 2001

This page was last modified in June 2004

[ NEI Home | Contact Us]
[ Health | Funding | News | Laboratories | Education | Jobs | About NEI | Resources | Help Viewing Site ]
[ NEI Privacy Statement | Accessibility | Disclaimer ]

We welcome your questions and comments. Please send general questions and comments to the NEI Office of Communication, Health Education, and Public Liaison. Technical questions about this website can be addressed to the NEI Website Manager.

H H S logo - link to U. S. Department of Health and Human Servicesd N I H logo - link to National Institutes of Healthd FirstGov

National Eye Institute
2020 Vision Place
Bethesda, MD 20892-3655
(301) 496-5248